Zobrazeno 1 - 10
of 582
pro vyhledávání: '"C. Hassel"'
Autor:
Barbara Meier-Schiesser, MD, PhD, Christine Zecha, MD, Sarah Zierold, MD, Isabel Kolm, MD, Magdalena Röckel, MD, Waltraud Fröhlich, Nora Mittag, MD, Christina Schmitt, MD, Joerg Kumbrink, PhD, Jessica C. Hassel, MD, Carola Berking, MD, Dorothee Nashan, MD, Lars Einar French, MD, Julio Vera-González, PhD, Reinhard Dummer, MD, Katrin Kerl-French, MD, Lucie Heinzerling, MD, MPH
Publikováno v:
JAAD International, Vol 15, Iss , Pp 157-164 (2024)
Background: Although highly efficacious, immune checkpoint inhibitors induce a multitude of immune-related adverse events including lichenoid skin reactions (irLP) that are often therapy-resistant. Objectives: To compare the clinical, histological, a
Externí odkaz:
https://doaj.org/article/51030e89392948efa51788f904e90ecb
Autor:
Jessica C Hassel, Alexander N Shoushtari, Omid Hamid, Takami Sato, Paul Nathan, Marcus O Butler, Jason J Luke, Richard D Carvajal, Leonel Hernandez-Aya, Douglas B Johnson, Laura Collins, Enrique Espinosa, Joseph J Sacco, Serge Leyvraz, Alexandra Ikeguchi, Matthew Rioth, Chris Holland, Josep M Piulats
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Background Tebentafusp, a bispecific (gp100×CD3) ImmTAC, significantly improved overall survival (OS) outcomes for HLA-A*02:01+ adult patients with untreated metastatic uveal melanoma (mUM) and showed promising survival in previously treated mUM wit
Externí odkaz:
https://doaj.org/article/b89b2a51187f4158bed6c6e774c8ce00
Autor:
Elias A. T. Koch, Anne Petzold, Edgar Dippel, Michael Erdmann, Anja Gesierich, Ralf Gutzmer, Jessica C. Hassel, Sebastian Haferkamp, Katharina C. Kähler, Nicole Kreuzberg, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Markus Meissner, Peter Mohr, Claudia Pföhler, Farnaz Rahimi, Beatrice Schell, Patrick Terheyden, Kai-Martin Thoms, Selma Ugurel, Jens Ulrich, Jochen Utikal, Michael Weichenthal, Fabian Ziller, Carola Berking, Markus V. Heppt
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionDespite recent advancements in the treatment of metastatic uveal melanoma (UM), the availability of further treatment options remains limited and the prognosis continues to be poor in many cases. In addition to tebentafusp, immune checkpo
Externí odkaz:
https://doaj.org/article/e37aacd9f05d43b681af7a4bbdfeb024
Publikováno v:
Cells, Vol 13, Iss 19, p 1615 (2024)
Non-melanoma skin cancer (NMSC) is primarily categorized into basal cell carcinoma (BCC), the most prevalent form of skin cancer, and cutaneous squamous cell carcinoma (cSCC), the second most common type. Both BCC and cSCC represent a significant hea
Externí odkaz:
https://doaj.org/article/482e99b3d2e445f593c99388914f0ec8
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Tissue-resident memory T cells (TRM cells) have become an interesting subject of study for antitumor immunity in melanoma and other solid tumors. In the initial phases of antitumor immunity, they maintain an immune equilibrium and protect against cha
Externí odkaz:
https://doaj.org/article/427014c9b54246779208e13aba6f1b69
Publikováno v:
Pharmaceutics, Vol 16, Iss 8, p 1046 (2024)
Uveal melanoma represents a rare and aggressive subtype of melanoma with limited treatment options and poor prognosis, especially in the metastatic setting. Tebentafusp, a bispecific fusion protein, offers a promising therapeutic approach by targetin
Externí odkaz:
https://doaj.org/article/0f4c66ed957c4876b5c48483889ce178
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 12, p 6532 (2024)
Chemokines and cytokines represent an emerging field of immunotherapy research. They are responsible for the crosstalk and chemoattraction of immune cells and tumor cells. For instance, CXCL9/10/11 chemoattract effector CD8+ T cells to the tumor micr
Externí odkaz:
https://doaj.org/article/c6cc6428933a453db1294f1ed69b945e
Autor:
Marten Meyer, Christina Parpoulas, Titouan Barthélémy, Jonas P. Becker, Pornpimol Charoentong, Yanhong Lyu, Selina Börsig, Nadja Bulbuc, Claudia Tessmer, Lisa Weinacht, David Ibberson, Patrick Schmidt, Rüdiger Pipkorn, Stefan B. Eichmüller, Peter Steinberger, Katharina Lindner, Isabel Poschke, Michael Platten, Stefan Fröhling, Angelika B. Riemer, Jessica C. Hassel, Maria Paula Roberti, Dirk Jäger, Inka Zörnig, Frank Momburg
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
Peptide-loaded MHC class I (pMHC-I) multimers have revolutionized our capabilities to monitor disease-associated T cell responses with high sensitivity and specificity. To improve the discovery of T cell receptors (TCR) targeting neoantigens of indiv
Externí odkaz:
https://doaj.org/article/2562f0907ae7489481331f6d349419cb
Autor:
Jan Leipe, Jessica C Hassel, Hanns-Martin Lorenz, Janine Günther, Manuel Feisst, Leonore Diekmann, Petros Christopoulos, Karolina Gente, Lea Daniello, Julia Will, Victor Olsavszky, M Margarida Souto-Carneiro
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Rheumatic immune-related adverse events (R-irAEs) occur in 5–15% of patients receiving immune checkpoint inhibitors (ICI) and, unlike other irAEs, tend to be chronic. Herein, we investigate the factors influencing cancer and R-irAEs outc
Externí odkaz:
https://doaj.org/article/2a66029fe121462dbd06630333efd7f8
Autor:
Dirk Schadendorf, Carola Berking, Jessica C Hassel, Lisa Zimmer, Ralf Gutzmer, Alexander Kreuter, Andrea Forschner, Bastian Schilling, Selma Ugurel, Katharina C Kähler, Peter Mohr, Patrick Terheyden, Felix Kiecker, Henner Stege, Sebastian Haferkamp, Friedegund Meier, Claudia Pfoehler, Dirk Debus, Rudolf Herbst, Carmen Loquai, Frank Meiss, Martin Kaatz, Jens Ulrich, Edgar Dippel, Michael Weichenthal, Axel Hauschild, Ulrike Leiter, Markus V Heppt, Christoffer Gebhardt, Michael Sachse, Fabian Ziller, Stephan Grabbe, Georg Lodde, Maximilian Haist, Friederike Rogall, Yuqi Tan, Imke von Wasielewski, Kai Christian Klespe, Michael Tronnier, Jan Christoph Simon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Adjuvant therapy with immune-checkpoint inhibitors (CPI) or BRAF/MEK-directed targeted therapy (TT) improves recurrence-free survival (RFS) for patients with advanced, BRAFV600-mutant (BRAFmut) resected melanoma. However, 40% of these pati
Externí odkaz:
https://doaj.org/article/b02d789393944e89a582fe64cc6e6ada